*** TEST ***
Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A

[thumbnail of Article] PDF (Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB
[thumbnail of Supplementary materials] PDF (Supplementary materials) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB

Item Type:Article
Title:Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A
Creators Name:Rohwer, N., Bindel, F., Grimm, C., Lin, S.J., Wappler, J., Klinger, B., Blüthgen, N., Du Bois, I., Schmeck, B., Lehrach, H., de Graauw, M., Goncalves, E., Saez-Rodriguez, J., Tan, P., Grabsch, H.I., Prigione, A., Kempa, S. and Cramer, T.
Abstract:Despite the approval of numerous molecular targeted drugs, long-term antiproliferative efficacy is rarely achieved and therapy resistance remains a central obstacle of cancer care. Combined inhibition of multiple cancer-driving pathways promises to improve antiproliferative efficacy. HIF-1 is a driver of gastric cancer and considered to be an attractive target for therapy. We noted that gastric cancer cells are able to functionally compensate the stable loss of HIF-1{alpha}. Via transcriptomics we identified a group of upregulated genes in HIF-1{alpha}-deficient cells and hypothesized that these genes confer survival upon HIF-1{alpha} loss. Strikingly, simultaneous knock-down of HIF-1{alpha} and Annexin A1 (ANXA1), one of the identified genes, resulted in complete cessation of proliferation. Using stable isotope-resolved metabolomics, oxidative and reductive glutamine metabolism was found to be significantly impaired in HIF-1{alpha}/ANXA1-deficient cells, potentially explaining the proliferation defect. In summary, we present a conceptually novel application of stable gene inactivation enabling in-depth deconstruction of resistance mechanisms. In theory, this experimental approach is applicable to any cancer-driving gene or pathway and promises to identify various new targets for combination therapies.
Keywords:Cancer Therapy, Annexin A1, Cancer Metabolism, HIF-1, Induced Essentiality, Animals, Mice
Source:Oncotarget
ISSN:1949-2553
Publisher:Impact Journals
Volume:7
Number:6
Page Range:6693-6710
Date:29 December 2015
Official Publication:https://doi.org/10.18632/oncotarget.6793
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library